American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes–2026. Diabetes Care. 2026;49(Suppl 1):S166–82.

Article  Google Scholar 

Nauck MA, Tuttle KR, Tschöp MH, et al. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892–908.

Article  CAS  PubMed  Google Scholar 

Kim D-H, Kim J-E. Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations. J Pharm Investig. 2025. https://doi.org/10.1007/s40005-025-00762-6.

Article  Google Scholar 

Isaacs DM, Kruger DF, Spollett GR. Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach. Diabetes Spectr. 2021;34(1):7–19.

Article  PubMed  PubMed Central  Google Scholar 

US FDA. WEGOVY (semaglutide): US prescribing information. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf. Accessed 10 June 2026.

US FDA. FOUNDAYO (orforglipron tablet): US prescribing information. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf. Accessed 10 June 2026.

Sloop KW, Cox AL, Wainscott DB, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16(778):1–16.

Article  Google Scholar 

US FDA. FDA approves first new molecular entity under National Priority Voucher program [media release]. 01 Apr 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program?utm_medium=email&utm_source=govdelivery.

Chugai Pharmaceutical. Chugai and Lilly enter into a license agreement for oral GLP-1 agonist, OWL833 [media release]. 27 Sep 2018. https://www.chugai-pharm.co.jp/news/cont_file_dl.php?f=180927eOWL833_License.pdf&src=[%0],[%1]&rep=130,551.

Google Patents. WO2023220109A1. 2023. https://patents.google.com/patent/WO2023220109A1/en. Accessed 10 June 2026.

Ma X, Li YG, Raha S, et al. Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight. Diabetes Obes Metab. 2026;28(7):5803–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci USA. 2020;117(47):29959–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927–44.

Article  PubMed  Google Scholar 

Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147–60.

Article  CAS  PubMed  Google Scholar 

Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796–806.

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065–76.

Article  CAS  PubMed  Google Scholar 

Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. https://doi.org/10.1038/s41591-026-04386-7.

Article  PubMed  PubMed Central  Google Scholar 

Welch MD, Forst TA, Jia W, et al. Orforglipron vs. dapagliflozin in type 2 diabetes inadequately controlled with metformin [abstract]. Diabetes. 2026;75(Suppl 1):1254-OR.

Giorgino F, Dsouza S, Ludwig L, et al. Efficacy and safety of orforglipron vs. placebo added to titrated insulin glargine in adults with long-standing type 2 diabetes: ACHIEVE-5 [abstract]. Diabetes. 2026;75(Suppl 1):1253-OR.

Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26–36.

Article  CAS  PubMed  Google Scholar 

Lubberding AF, Veedfald S, Achter JS, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120(12):1427–41.

Article  CAS  PubMed  PubMed Central  Google Scholar